The Direct Healthcare Cost of Stargardt Disease: A Claims-Based Analysis

References

• Walia S, Fishman GA. Natural history of phenotypic changes in Stargardt macular dystrophy. Ophthalmic Genet. 2009;30(2):63–68. doi:https://doi.org/10.1080/13816810802695550.
   PubMed Web of Science ®Google Scholar
• Haji Abdollahi S, Hirose T. Stargardt-Fundus flavimaculatus: recent advancements and treatment. Semin Ophthalmol. 2013;28(5–6):372–376. doi:https://doi.org/10.3109/08820538.2013.825286.
   PubMed Web of Science ®Google Scholar
• Lu LJ, Liu J, Adelman RA. Novel therapeutics for Stargardt disease. Graefes Arch Clin Exp Ophthalmol. 2017;255(6):1057–1062. doi:https://doi.org/10.1007/s00417-017-3619-8.
   PubMed Web of Science ®Google Scholar
• Auricchio A, Trapani I, Allikmets R. Gene therapy of ABCA4-associated diseases. Cold Spring Harb Perspect Med. 2015;5(5):a017301. doi:https://doi.org/10.1101/cshperspect.a017301.
   PubMed Web of Science ®Google Scholar
• Tanna P, Strauss RW, Fujinami K, Michaelides M. Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options. British J Ophthalmol. August 2016: bjophthalmol-2016-308823. doi:https://doi.org/10.1136/bjophthalmol-2016-308823.
   Google Scholar
• Armstrong JD, Meyer D, Xu S, Elfervig JL. Long-term follow-up of Stargardt’s disease and fundus flavimaculatus. Ophthalmology. 1998;105(3):448–457; discussion 457–458. doi:https://doi.org/10.1016/S0161-6420(98)93026-3.
   Google Scholar
• Westeneng-van Haaften SC, Boon CJF, Cremers FPM, Hoefsloot LH, den Hollander AI, Hoyng CB. Clinical and genetic characteristics of late-onset Stargardt’s disease. Ophthalmology. 2012;119(6):1199–1210. doi:https://doi.org/10.1016/j.ophtha.2012.01.005.
   PubMed Web of Science ®Google Scholar
• Halpern MT, Schmier JK, Covert D, Venkataraman K. Resource utilization and costs of age-related macular degeneration. Health Care Financ Rev. 2006;27:37–47.
   PubMedGoogle Scholar
• Schmier JK, Jones ML, Halpern MT. The burden of age-related macular degeneration. Pharmacoeconomics. 2006;24(4):319–334. doi:https://doi.org/10.2165/00019053-200624040-00003.
   PubMed Web of Science ®Google Scholar
• Macular degeneration treatment market size, share, trends | forecast. https://www.acumenresearchandconsulting.com/macular-degeneration-treatment-market. 2026. Accessed May 10, 2019.
   Google Scholar
• Hansen L IBM MarketScan Research Databases for life sciences researchers. 2018.
   Google Scholar
• Zahid S, Jayasundera T, Rhoades W, et al. Clinical phenotypes and prognostic full-field electroretinographic findings in Stargardt disease. Am J Ophthalmol. 2013;155(3):465–473.e3. doi:https://doi.org/10.1016/j.ajo.2012.09.011.
   PubMed Web of Science ®Google Scholar
• Bertakis KD, Azari R, Helms LJ, Callahan EJ, Robbins JA. Gender differences in the utilization of health care services. J Fam Pract. 2000;49:147–152.
   PubMed Web of Science ®Google Scholar
• Frick KD, Roebuck MC, Feldstein JI, McCarty CA, Grover LL. Health services utilization and cost of retinitis pigmentosa. Arch Ophthalmol. 2012;130(5):629–634. doi:https://doi.org/10.1001/archophthalmol.2011.2820.
   PubMedGoogle Scholar
• Schroeder L, Petrou S, Kennedy C, et al. The economic costs of congenital bilateral permanent childhood hearing impairment. Pediatrics. 2006;117(4):1101–1112. doi:https://doi.org/10.1542/peds.2005-1335.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global costs of unaddressed hearing loss and cost-effectiveness of interventions. http://apps.who.int/iris/bitstream/10665/254659/1/9789241512046-eng.pdf. 2017. Accessed September 16, 2019.
   Google Scholar
• National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on Public Health Approaches to Reduce Vision Impairment and Promote Eye Health; Welp A, Woodbury RB, McCoy MA, et al., editors. Making Eye Health a Population Health Imperative: Vision for Tomorrow. Washington (DC): National Academies Press (US); 2016 Sep 15. Available from: https://www.ncbi.nlm.nih.gov/books/NBK385157/ doi: https://doi.org/10.17226/23471
   Google Scholar
• Wittenborn JS, Zhang X, Feagan CW, et al. The economic burden of vision loss and eye disorders among the United States population younger than 40 years. Ophthalmology. 2013;120(9):1728–1735. doi:https://doi.org/10.1016/j.ophtha.2013.01.068.
   PubMed Web of Science ®Google Scholar
• Collee CM, Jalkh AE, Weiter JJ, Friedman GR. Visual Improvement with low vision aids in Stargardt’s disease. Ophthalmology. 1985;92(12):1657–1659. doi:https://doi.org/10.1016/S0161-6420(85)34086-1.
   PubMed Web of Science ®Google Scholar
• Schwartz SD, Hubschman J-P, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012;379(9817):713–720. doi:https://doi.org/10.1016/S0140-6736(12)60028-2.
   PubMed Web of Science ®Google Scholar
• Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015;385(9967):509–516. doi:https://doi.org/10.1016/S0140-6736(14)61376-3.
   PubMed Web of Science ®Google Scholar
• Schwartz SD, Tan G, Hosseini H, Nagiel A. Subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium for the treatment of macular degeneration: an assessment at 4 years. Invest Ophthalmol Vis Sci. 2016;57(5):ORSFc1–9. doi:https://doi.org/10.1167/iovs.15-18681.
   PubMed Web of Science ®Google Scholar
• Song WK, Park K-M, Kim H-J, et al. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients. Stem Cell Reports. 2015;4(5):860–872. doi:https://doi.org/10.1016/j.stemcr.2015.04.005.
   PubMed Web of Science ®Google Scholar
• Hussain RM, Ciulla TA, Berrocal AM, Gregori NZ, Flynn HW, Lam BL. Stargardt macular dystrophy and evolving therapies. Expert Opin Biol Ther. 2018;18(10):1049–1059. doi:https://doi.org/10.1080/14712598.2018.1513486.
   PubMed Web of Science ®Google Scholar
• da Cruz L, Fynes K, Georgiadis O, et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat Biotechnol. 2018;36(4):328–337. doi:https://doi.org/10.1038/nbt.4114.
   PubMed Web of Science ®Google Scholar
• De Silva SR, Charbel Issa P, Singh MS, et al. Single residue AAV capsid mutation improves transduction of photoreceptors in the Abca4-/- mouse and bipolar cells in the rd1 mouse and human retina ex vivo. Gene Ther. 2016;23(11):767–774. doi:https://doi.org/10.1038/gt.2016.54.
   PubMed Web of Science ®Google Scholar
• McClements ME, Barnard AR, Singh MS, et al. An AAV dual vector strategy ameliorates the stargardt phenotype in adult Abca4-/- mice. Hum Gene Ther. 2019;30(5):590–600. doi:https://doi.org/10.1089/hum.2018.156.
   PubMed Web of Science ®Google Scholar